NASDAQ:INCY - Incyte Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $86.31 +0.64 (+0.75 %) (As of 03/21/2019 01:19 AM ET)Previous Close$85.67Today's Range$85.38 - $87.2052-Week Range$57.00 - $89.75Volume742,777 shsAverage Volume1.53 million shsMarket Capitalization$18.48 billionP/E Ratio105.26Dividend YieldN/ABeta1.4 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve acute and chronic GVHD, as well as Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC); and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome, as well as a pivotal program for solid tumors with driver activations of FGF/FGFR. Further, it is involved in developing INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Additionally, the company develops Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Syros Pharmaceuticals, Inc.; and Innovent Biologics, Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware. Receive INCY News and Ratings via Email Sign-up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:INCY Previous Symbol CUSIP45337C10 CIK879169 Webwww.incyte.com Phone302-498-6700Debt Debt-to-Equity Ratio0.01 Current Ratio4.31 Quick Ratio4.29Price-To-Earnings Trailing P/E Ratio105.26 Forward P/E Ratio67.96 P/E GrowthN/A Sales & Book Value Annual Sales$1.88 billion Price / Sales9.82 Cash Flow$1.0985 per share Price / Cash Flow78.57 Book Value$9.05 per share Price / Book9.54Profitability EPS (Most Recent Fiscal Year)$0.82 Net Income$109.49 million Net Margins5.82% Return on Equity6.17% Return on Assets4.43%Miscellaneous Employees1,367 Outstanding Shares214,054,000Market Cap$18.48 billion Next Earnings Date5/7/2019 (Estimated) OptionableOptionable Incyte (NASDAQ:INCY) Frequently Asked Questions What is Incyte's stock symbol? Incyte trades on the NASDAQ under the ticker symbol "INCY." How were Incyte's earnings last quarter? Incyte Co. (NASDAQ:INCY) posted its quarterly earnings data on Thursday, February, 14th. The biopharmaceutical company reported $0.40 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.25 by $0.15. The biopharmaceutical company earned $528.40 million during the quarter, compared to analyst estimates of $485.72 million. Incyte had a net margin of 5.82% and a return on equity of 6.17%. The business's revenue for the quarter was up 19.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.02 EPS. View Incyte's Earnings History. When is Incyte's next earnings date? Incyte is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for Incyte. What price target have analysts set for INCY? 21 brokerages have issued twelve-month target prices for Incyte's shares. Their predictions range from $70.00 to $140.11. On average, they anticipate Incyte's share price to reach $93.5359 in the next twelve months. This suggests a possible upside of 8.4% from the stock's current price. View Analyst Price Targets for Incyte. What is the consensus analysts' recommendation for Incyte? 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 6 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Incyte. What are Wall Street analysts saying about Incyte stock? Here are some recent quotes from research analysts about Incyte stock: 1. According to Zacks Investment Research, "Incyte suffered a setback with failure of the phase III ECHO-301 study, evaluating epacadostat in combination with Keytruda. Further, the approval of the 4mg dose of baricitinib is doubtful. Moreover, Incyte’s dependence on only Jakafi is a concern as well. Shares have underperformed the industry in the year so far. Meanwhile, Incyte’s lead drug Jakafi continues to maintain momentum for the company as the underlying patient demand for the drug remains strong. Incyte’s sNDA, seeking a label expansion of Jakafi for the treatment of steroid-refractory acute GVHD, has been accepted for Priority Review by the FDA. The agency has set a target action date of Feb 24, 2019. An approval will further boost sales. The recent FDA approval of Olumiant 2 mg, for which Incyte received a milestone payment from Lilly, is a positive." (1/23/2019) 2. Raymond James analysts commented, "We are reiterating our Strong Buy rating for Incyte. This morning, the company announced that the FDA has accepted for priority review its supplemental new drug application (sNDA) for Jakafi for the treatment of patients with steroid-refractory acute graft versus host disease (SR-aGVHD). The priority review grants a 6 month review period by the FDA, resulting in a PDUFA date of approximately March 25, 2019. Based on positive data from the REACH1 study, we remain confident regarding Incyte’s expansion into the steroid refractory GVHD market, which we estimate to be a ~$500 million market opportunity in the U.S." (10/25/2018) 3. Cantor Fitzgerald analysts commented, ". We are increasing our price target to $74 from $73 and reiterating our Neutral rating on INCY. At the ongoing ESMO, INCY provided updated Fight-202 results in cholangiocarcinoma, which looked superior to the previously disclosed initial data. Additionally, in a late-breaker presentation, Novartis (NVS, Not Covered) reported Phase II results from its MET inhibitor capmatinib in MET-mutated advanced non-small cell lung cancer (NSCLC) patients. Note that NVS received worldwide rights for capmatinib from INCY. NVS reported promising response rate data that compare favorably to earlier reported results from any MET inhibitors." (10/21/2018) 4. JPMorgan Chase & Co. analysts commented, "INCY’s 1Q print/report (initial thoughts here; slides here) this morning was relatively uneventful. Following the success of REACH1 in acute GVHD, management is planning a regulatory filing in 3Q18 (recall Jakafi has BTD status) with plans for an immediate launch upon approval. Also, as previously disclosed, a filing for the FGFR inhibitor in cholangiocarcinoma is still anticipated in 2019, pending final data follow- up (interim data at recent investor day). We’re maintaining our OW given shares are trading at a discount to our DCF derived fair value for the base business. With that said, we suspect it will require some significant execution on the relatively broad pipeline for investors to more actively re-engage with the story." (8/1/2018) Has Incyte been receiving favorable news coverage? News stories about INCY stock have trended somewhat negative recently, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Incyte earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. Who are some of Incyte's key competitors? Some companies that are related to Incyte include Iqvia (IQV), EXACT Sciences (EXAS), Exelixis (EXEL), Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Eloxx Pharmaceuticals (ELOX), Sorrento Therapeutics (SRNE), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS) and Anavex Life Sciences (AVXL). What other stocks do shareholders of Incyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Celgene (CELG), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), BioMarin Pharmaceutical (BMRN), Intel (INTC), Applied Materials (AMAT) and AbbVie (ABBV). Who are Incyte's key executives? Incyte's management team includes the folowing people: Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 59)Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 56)Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 52)Ms. Christiana Stamoulis, Exec. VP & CFO (Age 48)Mr. Michael Morrissey, Head of Global Technical Operations & Corp. Sr. VP Who are Incyte's major shareholders? Incyte's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.17%), Norges Bank (1.37%), Geode Capital Management LLC (1.10%), Manning & Napier Group LLC (1.09%), Northern Trust Corp (0.93%) and First Trust Advisors LP (0.70%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, David W Gryska, Eric H Siegel, Herve Hoppenot, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Steven H Stein, Vijay K Iyengar and Yao Wenqing. View Institutional Ownership Trends for Incyte. Which major investors are selling Incyte stock? INCY stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Frontier Capital Management Co. LLC, Eaton Vance Management, Rhenman & Partners Asset Management AB, Millennium Management LLC, Amundi Pioneer Asset Management Inc., First Trust Advisors LP and Ashford Capital Management Inc.. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, Paul Trower, Paula J Swain, Vijay K Iyengar and Yao Wenqing. View Insider Buying and Selling for Incyte. Which major investors are buying Incyte stock? INCY stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Two Sigma Investments LP, Polar Capital LLP, Prudential PLC, Two Sigma Advisers LP, Sofinnova Investments Inc., Broadfin Capital LLC and BlackRock Inc.. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, Herve Hoppenot and Jean Jacques Bienaime. View Insider Buying and Selling for Incyte. How do I buy shares of Incyte? Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Incyte's stock price today? One share of INCY stock can currently be purchased for approximately $86.31. How big of a company is Incyte? Incyte has a market capitalization of $18.48 billion and generates $1.88 billion in revenue each year. The biopharmaceutical company earns $109.49 million in net income (profit) each year or $0.82 on an earnings per share basis. Incyte employs 1,367 workers across the globe. What is Incyte's official website? The official website for Incyte is http://www.incyte.com. How can I contact Incyte? Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected] MarketBeat Community Rating for Incyte (NASDAQ INCY)Community Ranking: 3.4 out of 5 ( )Outperform Votes: 995 (Vote Outperform)Underperform Votes: 474 (Vote Underperform)Total Votes: 1,469MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote "Outperform" if you believe INCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INCY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/21/2019 by MarketBeat.com StaffFeatured Article: When is a capital gain realized?